Erlotinib - Latest Advances

Biological Differences between EGFR ex19del and ex21L858R-Preclinical Models Using an Engineered Pair of Isogenic NSCLC Cell Lines with CRISPR Engineering

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: October 06, 2025

Honokiol in cancer: Roles in enhancing combination therapy efficacy and preventing post-transplant malignancies.

Journal: Tumor discovery

Published: September 29, 2025

RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC.

Journal: Future oncology (London, England)

Published: September 25, 2025

IGPR-1 Is Phosphorylated on the Immunoreceptor Tyrosine-Based Motif, Stimulates the AKT Pathway and Supports Melanoma Growth.

Journal: Biochemistry

Published: September 16, 2025

Sunvozertinib (Zegfrovy) for NSCLC.

Journal: The Medical letter on drugs and therapeutics

Published: September 09, 2025

Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis.

Journal: BMJ (Clinical research ed.)

Published: September 02, 2025

A Synthetic Hydrogel with Tunable Stiffness for Engineering Pancreatic Cancer Organoids and Drug Testing.

Journal: ACS biomaterials science & engineering

Published: August 11, 2025

Design, synthesis, and apoptotic antiproliferative activity of novel dihydropyrimidine-5-carbonitrile/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors endowed with antioxidant activity.

Journal: RSC advances

Published: August 04, 2025

A recurrent de novo damaging variant in EMP2 causes progressive symmetric erythrokeratoderma.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: August 04, 2025

Design, synthesis and biological evaluation of novel pyrazoline derivatives as dual EGFR/VEGFR-2 inhibitors for targeted cancer therapy.

Journal: Bioorganic chemistry

Published: July 30, 2025

A Cyclized Bivalent Aptamer-Based Protein Degrader Targeting Receptor Tyrosine Kinases Overcomes Resistance to Inhibitors in Lung Cancer.

Journal: ACS nano

Published: July 29, 2025

Click synthesis of some novel benzo[d]thiazole-1,2,3-triazole hybrid compounds with benzamide and/or benzoate tethers as EGFR-dependent signaling inhibitors against breast cancer.

Journal: RSC medicinal chemistry

Published: July 26, 2025

Filters

Biological Differences between EGFR ex19del and ex21L858R-Preclinical Models Using an Engineered Pair of Isogenic NSCLC Cell Lines with CRISPR Engineering

Biological Differences between EGFR ex19del and ex21L858R-Preclinical Models Using an Engineered Pair of Isogenic NSCLC Cell Lines with CRISPR Engineering

Honokiol in cancer: Roles in enhancing combination therapy efficacy and preventing post-transplant malignancies.

Honokiol in cancer: Roles in enhancing combination therapy efficacy and preventing post-transplant malignancies.

RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC.

RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC.

IGPR-1 Is Phosphorylated on the Immunoreceptor Tyrosine-Based Motif, Stimulates the AKT Pathway and Supports Melanoma Growth.

IGPR-1 Is Phosphorylated on the Immunoreceptor Tyrosine-Based Motif, Stimulates the AKT Pathway and Supports Melanoma Growth.

Sunvozertinib (Zegfrovy) for NSCLC.

Sunvozertinib (Zegfrovy) for NSCLC.

Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis.

Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis.

A Synthetic Hydrogel with Tunable Stiffness for Engineering Pancreatic Cancer Organoids and Drug Testing.

A Synthetic Hydrogel with Tunable Stiffness for Engineering Pancreatic Cancer Organoids and Drug Testing.

Design, synthesis, and apoptotic antiproliferative activity of novel dihydropyrimidine-5-carbonitrile/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors endowed with antioxidant activity.

Design, synthesis, and apoptotic antiproliferative activity of novel dihydropyrimidine-5-carbonitrile/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors endowed with antioxidant activity.

A recurrent de novo damaging variant in EMP2 causes progressive symmetric erythrokeratoderma.

A recurrent de novo damaging variant in EMP2 causes progressive symmetric erythrokeratoderma.

Design, synthesis and biological evaluation of novel pyrazoline derivatives as dual EGFR/VEGFR-2 inhibitors for targeted cancer therapy.

Design, synthesis and biological evaluation of novel pyrazoline derivatives as dual EGFR/VEGFR-2 inhibitors for targeted cancer therapy.

A Cyclized Bivalent Aptamer-Based Protein Degrader Targeting Receptor Tyrosine Kinases Overcomes Resistance to Inhibitors in Lung Cancer.

A Cyclized Bivalent Aptamer-Based Protein Degrader Targeting Receptor Tyrosine Kinases Overcomes Resistance to Inhibitors in Lung Cancer.

Click synthesis of some novel benzo[d]thiazole-1,2,3-triazole hybrid compounds with benzamide and/or benzoate tethers as EGFR-dependent signaling inhibitors against breast cancer.

Click synthesis of some novel benzo[d]thiazole-1,2,3-triazole hybrid compounds with benzamide and/or benzoate tethers as EGFR-dependent signaling inhibitors against breast cancer.